---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004581"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:48:24.872572+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics reports $102.9M cash; updates on CAN-2409 BLA timeline and 2025 milestones

## Summary
- Cash and equivalents $102.9M (unaudited) at Dec 31, 2024, vs $35.4M at end-2023; provides runway into Q1 2027.
- CAN-2409 BLA submission for prostate cancer on track for Q4 2026; phase 3 data to be presented at upcoming scientific conference.
- Updated overall survival data for CAN-2409 in pancreatic and lung cancer expected Q1 2025.
- Phase 1b CAN-3110 overall survival data in recurrent high-grade glioma expected Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-004581
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/0000950170-25-004581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/cadl-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004581
- JSON: https://secwatch.observer/filing/0000950170-25-004581.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.